

# Incremental Exposure

## was the second dose worse than the first?

Here is the data taken from Pfizer's trials. These results were submitted by Pfizer to the FDA in December 2020. The Pfizer report is found here -

<https://web.facebook.com/groups/352273635911627/permalink/509390430199946>

### What do the Results Show?

<b>(Any Severity)</b>	<b>% of vaccinated having this symptom</b>		
<b>Pathology</b>	<b>1<sup>st</sup> Dose</b>	<b>2<sup>nd</sup> Dose</b>	<b>How much worse?</b>
Fever	3.7%	15.8%	4.3 times
Fatigue	47.4%	59.4%	1.25 times
Headache	41.9%	51.7%	1.23 times
Chills	14%	35.1%	2.5 times
Vomiting	1.2%	1.9%	1.6 times
Diarrhea	11.1%	10.4%	0.93 times
Muscle Pain	21.3%	37.3%	1.75 times
Joint Pain	11%	21.9%	2 times

These results show that the second dose is worse than the first.

### Here are the numbers for SEVERE reactions

<b>(SEVERE)</b>	<b>% of vaccinated having this symptom</b>		
<b>Pathology</b>	<b>1<sup>st</sup> Dose</b>	<b>2<sup>nd</sup> Dose</b>	<b>How much worse?</b>
Fever	0.3%	1.2%	4 times
Fatigue	1.4%	4.6%	3.3 times
Headache	1%	3.2%	3.2 times
Chills	0.4%	2.1%	5 times
Vomiting	0%	0.2%	2 times
Diarrhea	0.1%	0.2%	2 times
Muscle Pain	0.6%	2.2%	1.75 times
Joint Pain	0.2%	1%	5 times

## Here are the numbers for MODERATE reactions

<b>(MODERATE)</b>	<b>% of vaccinated having this symptom</b>		<b>How much worse?</b>
	<b>1<sup>st</sup> Dose</b>	<b>2<sup>nd</sup> Dose</b>	
<b>Fever</b>	<b>0.7%</b>	<b>5.2%</b>	<b>7.4 times</b>
<b>Fatigue</b>	<b>19.9%</b>	<b>33.7%</b>	<b>1.69 times</b>
<b>Headache</b>	<b>13.4%</b>	<b>22.9%</b>	<b>1.7 times</b>
<b>Chills</b>	<b>3.6%</b>	<b>15.9%</b>	<b>4.4 times</b>
<b>Vomiting</b>	<b>0.2%</b>	<b>0.4%</b>	<b>2 times</b>
<b>Diarrhea</b>	<b>2%</b>	<b>1.7%</b>	<b>0.85 times</b>
<b>Muscle Pain</b>	<b>9.5%</b>	<b>19.5%</b>	<b>2 times</b>
<b>Joint Pain</b>	<b>4.3%</b>	<b>11.2%</b>	<b>2.6 times</b>

Whilst severe muscle and joint pain is completely disabling, even moderate pain can greatly diminish your quality of life and things you can do.

In the SEVERE category, severe headaches and severe fatigue are experienced after the second dose by 3.2% and 4.6% of all those vaccinated. Severe muscle pain is experienced by 2.2%. These are very high percentages.

### Conclusion

The second dose is worse than the first.

Assuming that both doses are identical in ingredients, then damage must be cumulative.

If you had a bad reaction to the first dose, then the second dose may be worse, and the third dose worse still, and the fourth dose even worse, simply because you are exposing your body to a repeat of the damage you suffered from the first dose.

Take a look at the percentages of vaccinated people suffering. These are high percentages. The odds are not as good as main stream media would have you believe.

### Intent

Incremental exposure to a toxin is less noticeable than full immediate exposure. You should ask yourself why the Governments are requiring people to take regular, repeated shots of a substance – causing a progressive accumulation of internal damage each time.

**Table 17. Frequency of Solicited Systemic Adverse Events Within 7 Days After Each Vaccination-Reactogenicity Subset of the Phase 2/3 Safety Population\*, 18 to 55 Years of Age**

<b>Adverse Event</b>	<b>BNT162b2 Dose 1 N=2238 n (%)</b>	<b>Placebo Dose 1 N=2248 n (%)</b>	<b>BNT162b2 Dose 2 N=2045 n (%)</b>	<b>Placebo Dose 2 N=2053 n (%)</b>
<b>Fever</b>				
≥38.0°C	85 (3.7)	20 (0.9)	331 (15.8)	10 (0.5)
>38.0°C to 38.4°C	64 (2.8)	10 (0.4)	194 (9.2)	5 (0.2)
>38.4°C to 38.9°C	15 (0.7)	5 (0.2)	110 (5.2)	3 (0.1)
>38.9°C to 40.0°C	6 (0.3)	3 (0.1)	26 (1.2)	2 (0.1)
>40.0°C	0 (0.0)	2 (0.1)	1 (0.0)	0 (0.0)
<b>Fatigue<sup>a</sup></b>				
Any	1085 (47.4)	767 (33.4)	1247 (59.4)	479 (22.8)
Mild	597 (26.1)	46 (20.3)	442 (21.1)	248 (11.8)
Moderate	455 (19.9)	289 (12.6)	708 (33.7)	217 (10.3)
Severe	33 (1.4)	11 (0.5)	97 (4.6)	14 (0.7)
<b>Headache<sup>a</sup></b>				
Any	959 (41.9)	775 (33.7)	1085 (51.7)	506 (24.1)
Mild	628 (27.4)	505 (22.0)	538 (25.6)	321 (15.3)
Moderate	308 (13.4)	251 (10.9)	480 (22.9)	170 (8.1)
Severe	23 (1.0)	19 (0.8)	67 (3.2)	15 (0.7)
<b>Chills<sup>a</sup></b>				
Any	321 (14.0)	146 (6.4)	737 (35.1)	79 (3.8)
Mild	230 (10.0)	111 (4.8)	359 (17.1)	65 (3.1)
Moderate	82 (3.6)	33 (1.4)	333 (15.9)	14 (0.7)
Severe	9 (0.4)	2 (0.1)	45 (2.1)	0 (0.0)
<b>Vomiting<sup>b</sup></b>				
Any	28 (1.2)	28 (1.2)	40 (1.9)	25 (1.2)
Mild	24 (1.0)	22 (1.0)	28 (1.3)	16 (0.8)
Moderate	4 (0.2)	5 (0.2)	8 (0.4)	9 (0.4)
Severe	0 (0.0)	1 (0.0)	4 (0.2)	0 (0.0)
<b>Diarrhea<sup>c</sup></b>				
Any	255 (11.1)	270 (11.7)	219 (10.4)	177 (8.4)
Mild	206 (9.0)	217 (9.4)	179 (8.5)	144 (6.8)
Moderate	46 (2.0)	52 (2.3)	36 (1.7)	32 (1.5)
Severe	3 (0.1)	1 (0.0)	4 (0.2)	1 (0.0)
<b>New or worsened muscle pain<sup>a</sup></b>				
Any	487 (21.3)	249 (10.8)	783 (37.3)	173 (8.2)
Mild	256 (11.2)	175 (7.6)	326 (15.5)	111 (5.3)
Moderate	218 (9.5)	72 (3.1)	410 (19.5)	59 (2.8)
Severe	13 (0.6)	2 (0.1)	47 (2.2)	3 (0.1)
<b>New or worsened joint pain<sup>a</sup></b>				
Any	251 (11.0)	138 (6.0)	459 (21.9)	109 (5.2)
Mild	147 (6.4)	95 (4.1)	205 (9.8)	54 (2.6)
Moderate	99 (4.3)	43 (1.9)	234 (11.2)	51 (2.4)
Severe	5 (0.2)	0 (0.0)	20 (1.0)	4 (0.2)
<b>Use of antipyretic or pain medication</b>	638 (27.8)	332 (14.4)	945 (45.0)	266 (12.6)

Source: adapted from EUA 27036, amendment 3, Table 19.

n = number of participants with the specified reaction.

N = number of participants in the reactogenicity subset reporting at least 1 yes or no response for the specified reaction after the specified dose.

<sup>a</sup> Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity.

<sup>b</sup> Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration.

<sup>c</sup> Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours.

\* Participants in the reactogenicity subset of the safety population ≥16 years of age enrolled by October 9, 2020 and received at least 1 dose of vaccine or placebo.

Data analysis cutoff date: November 14, 2020.